Video

Dr. Santos on the Utilization of Approved Monotherapies in NSCLC

Edgardo S. Santos, MD, FACP, discusses the utilization of approved monotherapies in non–small cell lung cancer.

Edgardo S. Santos, MD, FACP, clinical affiliate associate professor, Charles E. Schmidt College of Medicine, Florida Atlantic University, founding partner, Florida Precision Oncology, discusses the utilization of approved monotherapies in non–small cell lung cancer (NSCLC).

There are several monotherapies approved across the treatment landscape, not only in the United States, but in other countries as well, Santos says. In the United States, there are currently 3 single-agent checkpoint inhibitors approved including pembrolizumab (Keytruda), atezolizumab (Tecentriq), and cemiplimab (Libtayo), Santos explains. Overall, it has been essential to have these PD-1/PD-L1 inhibitors available for use in the armamentarium, Santos adds.

Moreover, monotherapy makes a difference when utilized in NSCLC when the PD-L1 expression is above 50%, Santos continues. Additionally, the approval of cemiplimab in the United States was based on data from the EMPOWER-Lung 1 trial (NCT03088540), Santos says.

Related Videos
James J. Harding, MD, associate attending physician, Memorial Sloan Kettering Cancer Center
J. Bradley Elder, MD
Rimas V. Lukas, MD
Adam E. Singer, MD, PhD, Health Sciences Clinical Instructor, medicine, division lead, kidney cancer, Division of Hematology/Oncology, UCLA Health
Diane Reidy-Lagunes, MD, vice chair, Oncology Operations, Regional Care Network, Memorial Sloan Kettering Cancer Center
Shubham Pant, MD, MBBS
Kevin Kalinsky, MD, MS, professor, Department of Hematology and Medical Oncology, director, Division of Medical Oncology, Department of Hematology and Medical Oncology, Emory University School of Medicine; Louisa and Rand Glenn Family Chair in Breast Cancer Research, director, Glenn Family Breast Center, director, Breast Medical Oncology, Winship Cancer Institute of Emory University
Brett L. Ecker, MD
Benjamin Garmezy, MD, assistant director, Genitourinary Research, Sarah Cannon Research Institute
Yelena Y. Janjigian, MD, chief, Gastrointestinal Oncology Service, Memorial Sloan Kettering Cancer Center